GLP-1s are transforming the management of obesity – an area where consumers hold huge sway. Using insights from Ipsos' Consumer Obesity Monitor, assess ongoing anti-obesity medication & GLP-1 demand, track shifts in consumer expectations, and assess the impact of such treatments on their lifestyles.
Through usage of GLP-1s, the obesity treatment landscape is undergoing massive transformation; several associated comorbidities may be next. Consisting of four key modular elements, this report – using Ipsos' Obesity & Cardiometabolic Therapy Monitor data - will help optimise strategies for those with both developmental or commercial interests in this field.
2024's approval of the first indicated drug to treat MASH, coupled with a rich developmental pipeline, sees this landscape on the precipice of change. Consisting of four key modular elements, this report – using Ipsos' MASH Therapy Monitor data - will help optimise strategies for those looking to shape the future of this therapeutic environment.
The treatment of MASH, an advanced form of fatty liver disease, is at a critical juncture. Using physician perceptions from our MASH Future Patient Journey Monitor, this report offers insights into HCP roles, care pathway changes - and the potential impact of out-of-pocket GLP-1 availability.
GLP-1 receptor agonists are transforming the treatment landscape for some of the world's most prevalent diseases. Using perceptual insights captured across a wide array of HCP specialist types, this report equips its reader with an in-depth understanding of both current and future GLP-1 prescribing intentions across multiple diseases.
With GLP-1s creating increasingly dynamic social conversation, how do you separate the noise from the strategic signal? In this series of modular reports, we use Ipsos Synthesio’s proprietary Signals GenAI tool to decode millions of real-time social media conversations and transforms them into actionable intelligence for brands in the GLP-1 space.
This report delivers a targeted analysis of the anaemia treatment landscape in chronic kidney disease (CKD) within Japan, one of the world’s most mature nephrology markets and an early adopter of the HIF prolyl hydroxylase inhibitors (HIF-PHIs). Leveraging tracked market data between 2020-2022, this analysis provides evidence-based insights into shifting treatment dynamics following the 2019 launch of roxadustat.